bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from CD4+ T Lymphocyte Ablation Prevents Pancreatic Carcinogenesis in Mice
Authors: Zhang Yaqing , Yan Wei , Mathew Esha , Bednar Filip , Wan Shanshan , Collins Meredith A. , Evans Rebecca A. , Welling Theodore H. , Vonderheide Robert H. , di Magliano Marina Pasca
Published: April 2023

PDF file - 8114K, CD4 deficiency prevents ADM/PanIN lesions progression over time.
Supplemental table 1 from Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity
Authors: Yao Jun , Caballero Otavia L. , Huang Ying , Lin Calvin , Rimoldi Donata , Behren Andreas , Cebon Jonathan S. , Hung Mien-Chie , Weinstein John N. , Strausberg Robert L. , Zhao Qi
Published: April 2023

Table for correlation of ESRP1 expression and cytolytic activity in cancers.
Supplemental figure S1A, S1B, S2A, S2B, S3 from Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity
Authors: Yao Jun , Caballero Otavia L. , Huang Ying , Lin Calvin , Rimoldi Donata , Behren Andreas , Cebon Jonathan S. , Hung Mien-Chie , Weinstein John N. , Strausberg Robert L. , Zhao Qi
Published: April 2023

Figure S1, The truncated ESRP1 is only detected in melanoma but not other tumor types. Figure S2, Estimation of keratinocyte contamination using KRT2 and LOR expression. Figure S3, Conservation of E-box motif in intron 12 of ESRP1 among mammals.
Supplemental Table S3 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Authors: Tchou Julia , Zhao Yangbing , Levine Bruce L. , Zhang Paul J , Davis Megan M. , Melenhorst Jan Joseph , Kulikovskaya Irina , Brennan Andrea L , Liu Xiaojun , Lacey Simon F. , Posey Avery D. , Williams Austin D. , So Alycia , Conejo-Garcia Jose R. , Plesa Gabriela , Young Regina M. , McGettigan Shannon , Campbell Jean , Pierce Robert H. , Matro Jennifer M. , DeMichele Angela M. , Clark Amy S. , Cooper Laurence J. , Schuchter Lynn M. , Vonderheide Robert H. , June Carl H.
Published: April 2023

S3. Serial quantification of serum IL6 from a patient with prolonged subjectove myalgia post IT injection of mRNA c-Met CAR T cells.
Supplemental Table S1 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Authors: Tchou Julia , Zhao Yangbing , Levine Bruce L. , Zhang Paul J , Davis Megan M. , Melenhorst Jan Joseph , Kulikovskaya Irina , Brennan Andrea L , Liu Xiaojun , Lacey Simon F. , Posey Avery D. , Williams Austin D. , So Alycia , Conejo-Garcia Jose R. , Plesa Gabriela , Young Regina M. , McGettigan Shannon , Campbell Jean , Pierce Robert H. , Matro Jennifer M. , DeMichele Angela M. , Clark Amy S. , Cooper Laurence J. , Schuchter Lynn M. , Vonderheide Robert H. , June Carl H.
Published: April 2023

S1. Association of c-Met positive breast cancer with prognostic variables.
Supplementary Table 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Authors: Hodi F. Stephen , Lawrence Donald , Lezcano Cecilia , Wu Xinqi , Zhou Jun , Sasada Tetsuro , Zeng Wanyong , Giobbie-Hurder Anita , Atkins Michael B. , Ibrahim Nageatte , Friedlander Philip , Flaherty Keith T. , Murphy George F. , Rodig Scott , Velazquez Elsa F. , Mihm Martin C. , Russell Sara , DiPiro Pamela J. , Yap Jeffrey T. , Ramaiya Nikhil , Van den Abbeele Annick D. , Gargano Maria , McDermott David
Published: April 2023

PDF file - 39K, Summary of grade 3 and grade 4 events incidence at each dose level for all events and those events possibly, probably, or definitively related.
Supplementary Table 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Authors: Hodi F. Stephen , Lawrence Donald , Lezcano Cecilia , Wu Xinqi , Zhou Jun , Sasada Tetsuro , Zeng Wanyong , Giobbie-Hurder Anita , Atkins Michael B. , Ibrahim Nageatte , Friedlander Philip , Flaherty Keith T. , Murphy George F. , Rodig Scott , Velazquez Elsa F. , Mihm Martin C. , Russell Sara , DiPiro Pamela J. , Yap Jeffrey T. , Ramaiya Nikhil , Van den Abbeele Annick D. , Gargano Maria , McDermott David
Published: April 2023

PDF file - 139K, Worst grade adverse event for individual patients that occurred within the first twelve weeks of treatment (induction dose-limiting toxicity period). Adverse events recorded multiple times for any patient are reported only once according to the worst grade.
Supplementary Figure 5 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Authors: Hodi F. Stephen , Lawrence Donald , Lezcano Cecilia , Wu Xinqi , Zhou Jun , Sasada Tetsuro , Zeng Wanyong , Giobbie-Hurder Anita , Atkins Michael B. , Ibrahim Nageatte , Friedlander Philip , Flaherty Keith T. , Murphy George F. , Rodig Scott , Velazquez Elsa F. , Mihm Martin C. , Russell Sara , DiPiro Pamela J. , Yap Jeffrey T. , Ramaiya Nikhil , Van den Abbeele Annick D. , Gargano Maria , McDermott David
Published: April 2023

PDF file - 68K, A. Axial CT section of the chest at baseline demonstrates two nodules in the right lung, the dominant one in the lower lobe (white arrows). B. Follow-up CT 3 months after start of treatment demonstrates resolution of one of the nodules and no change in the other nodule. C. Axial CT section 8 months after start of treatment demonstrates complete resolution of the dominant lung nodule.
Supplementary Figure 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Authors: Hodi F. Stephen , Lawrence Donald , Lezcano Cecilia , Wu Xinqi , Zhou Jun , Sasada Tetsuro , Zeng Wanyong , Giobbie-Hurder Anita , Atkins Michael B. , Ibrahim Nageatte , Friedlander Philip , Flaherty Keith T. , Murphy George F. , Rodig Scott , Velazquez Elsa F. , Mihm Martin C. , Russell Sara , DiPiro Pamela J. , Yap Jeffrey T. , Ramaiya Nikhil , Van den Abbeele Annick D. , Gargano Maria , McDermott David
Published: April 2023

PDF file - 64K, Illustrations of the variation in pathologic responses to treatment. Examples of intermediate and no response.
Supplementary Figure 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Authors: Hodi F. Stephen , Lawrence Donald , Lezcano Cecilia , Wu Xinqi , Zhou Jun , Sasada Tetsuro , Zeng Wanyong , Giobbie-Hurder Anita , Atkins Michael B. , Ibrahim Nageatte , Friedlander Philip , Flaherty Keith T. , Murphy George F. , Rodig Scott , Velazquez Elsa F. , Mihm Martin C. , Russell Sara , DiPiro Pamela J. , Yap Jeffrey T. , Ramaiya Nikhil , Van den Abbeele Annick D. , Gargano Maria , McDermott David
Published: April 2023

PDF file - 74K, High-power H&E and CD31 stained post treatment biopsy of intratumoral vessels. The endothelial cells appear morphologically columnar. CD31 staining is concentrated at the interendothelial junctions (arrows).
Supplementary Figures 1 through 8 from Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Authors: Newick Kheng , O'Brien Shaun , Sun Jing , Kapoor Veena , Maceyko Steven , Lo Albert , Puré Ellen , Moon Edmund , Albelda Steven M.
Published: April 2023

Supplemental Figure 1. Schematic representations of viral-engineered constructs for transductions of T cells. Supplemental Figure 2. Successful transduction of primary T cells and detection of transgenes. Supplemental Figure 3. Phenotypic characterization of human CAR T cells at baseline. Supplemental Figure 4. Phenotypic characterization of murine CAR T cells at baseline. Supplemental Figure 5. Heightened cytokine production by CAR-RIAD T cells upon in vitro restimulation with mesothelin-coated beads. Supplemental Figure 6. Densitometry analyses of signaling proteins. Supplemental Figure 7. Expression of PGE2 in our tumor cells and the effect of mesoCAR-RIAD T cells on tumors that do not express the antigen mesothelin. Supplemental Figure 8. Greater influx of CD4+ CAR T cells in human and murine tumors.
Supplementary Figure S5 from The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues
Authors: Wang Ting , Wang Changxi , Wu Jinghua , He Chenyang , Zhang Wei , Liu Jiayun , Zhang Ruifang , Lv Yonggang , Li Yongping , Zeng Xiaojing , Cao Hongzhi , Zhang Xiuqing , Xu Xun , Huang Chen , Wang Ling , Liu Xiao
Published: April 2023

Expanded clones (>0.1%) percentage in tumor tissue and lymph node.
Supplementary Figure S4 from The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues
Authors: Wang Ting , Wang Changxi , Wu Jinghua , He Chenyang , Zhang Wei , Liu Jiayun , Zhang Ruifang , Lv Yonggang , Li Yongping , Zeng Xiaojing , Cao Hongzhi , Zhang Xiuqing , Xu Xun , Huang Chen , Wang Ling , Liu Xiao
Published: April 2023

Shared clone frequency between lymph node and tumor tissue in lymph node and tumor tissue.
Supplementary Figure S3 from The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues
Authors: Wang Ting , Wang Changxi , Wu Jinghua , He Chenyang , Zhang Wei , Liu Jiayun , Zhang Ruifang , Lv Yonggang , Li Yongping , Zeng Xiaojing , Cao Hongzhi , Zhang Xiuqing , Xu Xun , Huang Chen , Wang Ling , Liu Xiao
Published: April 2023

Comparison of TRBV or TRBJ segment usage between tumor tissue and other two tissues.
supplemental figure 1 from Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Authors: Weber Jeffrey , Gibney Geoffrey , Kudchadkar Ragini , Yu Bin , Cheng Pingyan , Martinez Alberto J. , Kroeger Jodie , Richards Allison , McCormick Lori , Moberg Valerie , Cronin Heather , Zhao Xiuhua , Schell Michael , Chen Yian Ann
Published: April 2023

Gating Strategy for MDSC
Supplementary Figures 1 through 12 from Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non–Small Cell Lung Cancer
Authors: Zhang Xuyao , Fan Jiajun , Wang Shaofei , Li Yubin , Wang Yichen , Li Song , Luan Jingyun , Wang Ziyu , Song Ping , Chen Qicheng , Tian Wenzhi , Ju Dianwen
Published: April 2023

Supplementary Figure S1. The designed amino acid sequence of SIRPalphaD1-Fc. Supplementary Figure S2. Macrophage-mediated cytotoxicity in NSCLC cells after treatment with SIRPalphaD1-Fc. Supplementary Figure S3. SIRPalphaD1-Fc induced accumulation of autophagosomes and triggered autophagic flux in NSCLC cells. Supplementary Figure S4. Inhibiting autophagy enhanced macrophage-mediated phagocytosis. Supplementary Figure S5. Rapamycin exhibited negligible effect on the cytotoxicity mediated by macrophage against NSCLC cells. Supplementary Figure S6. Inactivation of Akt/mTOR signaling pathway after NSCLC cells treated with SIRPalphaD1-Fc. Supplementary Figure S7. Inactivation of Akt/mTOR signaling pathway in vivo after SIRPalphaD1-Fc treatment. Supplementary Figure S8. Representative fluorescence images of A549 cells co-stained with Cyto-ID(c) green dye and MitoSox(tm) red dye after exposed to SIRPalphaD1-Fc for the indicated time. Supplementary Figure S9. Photos of NSCLC xenograft tumors after treatment with SIRPalphaD1-Fc and/or chloroquine. Supplementary Figure S10. Analysis of SIRPalphaD1-Fc-treated A549 xenograft tumor tissues by TEM, H&E and immunohistochemistry staining. Supplementary Figure S11. Representative fluorescence images of ROS formation in NCI-H1975 xenograft tumors. Supplementary Figure S12. Simultaneously targeting CD47 and autophagy activated apoptosis-related pathways in vivo.
Supplemental Figure 3. ELISPOT responses to ATP6S1 in stage IV patients following CTLA4 blockade with ipilimumab. from Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma
Authors: Zhou Jun , Gupta Meghna , Wu Xinqi , Yoon Charles , Giobbie-Hurder Anita , Hodi F. Stephen
Published: April 2023

(A) Positive responses to peptide pools of ATP6S1. (B) Positive responses to individual peptide of ATP6S1.
Supplemental Figure 1. ELISPOT responses to ATP6S1 in stage III and IV melanoma patients. from Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma
Authors: Zhou Jun , Gupta Meghna , Wu Xinqi , Yoon Charles , Giobbie-Hurder Anita , Hodi F. Stephen
Published: April 2023

(A) Positive responses to overlapping peptide pools by ELISPOT. (B) Positive responses to individual peptide by ELISPOT. Intra-assay variability was based on 8 peptides of patients 6, 53, and 110. Each of which was run in duplicate on the same plate. The within-plate percent coefficient of variation for each peptide was calculated by dividing the standard deviation of each replicate pair by its mean and multiplying by 100. The average of the peptide coefficients of variation is reported as the intra-assay coefficient of variation. The intra-assay variability was 10.5%. The inter-assay variability was based on four different peptides (ATP 13, 14, 23, and 32) that were run in duplicate on two different plates to monitor plate-to-plate variation. Plate means were calculated for each peptide. The pairs of plate means were used to calculate a mean, standard deviation, and percent coefficient of variability for each peptide. The inter-assay variability reported is the average percent coefficient of variability of the four peptides. The inter-assay variability was 25.6%.
Supplementary Figure Legends from PD-1 Blockade Expands Intratumoral Memory T Cells
Authors: Ribas Antoni , Shin Daniel Sanghoon , Zaretsky Jesse , Frederiksen Juliet , Cornish Andrew , Avramis Earl , Seja Elizabeth , Kivork Christine , Siebert Janet , Kaplan-Lefko Paula , Wang Xiaoyan , Chmielowski Bartosz , Glaspy John A. , Tumeh Paul C. , Chodon Thinle , Pe'er Dana , Comin-Anduix Begoña
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 4 from PD-1 Blockade Expands Intratumoral Memory T Cells
Authors: Ribas Antoni , Shin Daniel Sanghoon , Zaretsky Jesse , Frederiksen Juliet , Cornish Andrew , Avramis Earl , Seja Elizabeth , Kivork Christine , Siebert Janet , Kaplan-Lefko Paula , Wang Xiaoyan , Chmielowski Bartosz , Glaspy John A. , Tumeh Paul C. , Chodon Thinle , Pe'er Dana , Comin-Anduix Begoña
Published: April 2023

. Gating strategy used to study T memory stem and T naïve-like T cell subpopulations within tumor-infiltrating lymphocytes. Dendrogram on the top, and the results of applying Boolean gates on the bottom. X-axis subpopulation of T cells as CD4, CD8 and DN T cells. Y axis, frequency of memory stem cells (MSC) and T naïve-like T cells. B = baseline; P = on therapy; n = 11.
Supplementary Figure 2 from PD-1 Blockade Expands Intratumoral Memory T Cells
Authors: Ribas Antoni , Shin Daniel Sanghoon , Zaretsky Jesse , Frederiksen Juliet , Cornish Andrew , Avramis Earl , Seja Elizabeth , Kivork Christine , Siebert Janet , Kaplan-Lefko Paula , Wang Xiaoyan , Chmielowski Bartosz , Glaspy John A. , Tumeh Paul C. , Chodon Thinle , Pe'er Dana , Comin-Anduix Begoña
Published: April 2023

Activation status of T and B cells. (A) T cell gating strategy. T cells from Fig. S1, were split into CD4+ and CD4- (CD8+) T subsets, and subsequently analyzed for the activation markers CD25 and HLA-DR. (B) Percentage of activated CD4+ and CD8 (CD4-) T cell subsets. (C) B cell gating strategy. From B cells, the activation marker HLA-DR (black box) was quantified. (D) Percentage of activated B cells on therapy. Biexponential displaying was done for the dot plots. Mean and {plus minus} SD are provided. B = before treatment; P = on anti-PD-1 therapy; n = number of biopsies analyzed. Solid circles represent responders; open circles represent non-responders (n= 26 baseline; n= 22 on therapy).
Supplementary Figure S3 from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Authors: Zigler Maya , Shir Alexei , Joubran Salim , Sagalov Anna , Klein Shoshana , Edinger Nufar , Lau Jeffrey , Yu Shang-Fan , Mizraji Gabriel , Globerson Levin Anat , Sliwkowski Mark X. , Levitzki Alexander
Published: April 2023

Supplementary Figure demonstrating the effect of pIC/PPHAffibody treatment on RENCA HER2 cell survival in vitro and in vivo by immunohistochemistry staining for c-caspase-3
Supplementary Table S3 from Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma
Authors: Matsushita Hirokazu , Sato Yusuke , Karasaki Takahiro , Nakagawa Tohru , Kume Haruki , Ogawa Seishi , Homma Yukio , Kakimi Kazuhiro
Published: April 2023

Mutations, HLA types neoepitopes, and predicted HLA binding
Supplementary Table S1 from 4-1BB–Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells
Authors: Harao Michiko , Forget Marie-Andrée , Roszik Jason , Gao Hui , Babiera Gildy V. , Krishnamurthy Savitri , Chacon Jessica A. , Li Shumin , Mittendorf Elizabeth A. , DeSnyder Sarah M. , Rockwood Korrene F. , Bernatchez Chantale , Ueno Naoto T. , Radvanyi Laszlo G. , Vence Luis , Haymaker Cara , Reuben James M.
Published: April 2023

BC7 peptides
Supplementary Figure 2 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
Authors: Shen Li , Sundstedt Anette , Ciesielski Michael , Miles Kiersten Marie , Celander Mona , Adelaiye Remi , Orillion Ashley , Ciamporcero Eric , Ramakrishnan Swathi , Ellis Leigh , Fenstermaker Robert , Abrams Scott I. , Eriksson Helena , Leanderson Tomas , Olsson Anders , Pili Roberto
Published: April 2023

Supplementary Figure 2. Tasquinimod modulation of MDSC subpopulations in CR Myc-CaP tumor bearing FVB mice.
Supplemental Figure 7 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Authors: Wang Enxiu , Wang Liang-Chuan , Tsai Ching-Yi , Bhoj Vijay , Gershenson Zack , Moon Edmund , Newick Kheng , Sun Jing , Lo Albert , Baradet Timothy , Feldman Michael D. , Barrett David , Puré Ellen , Albelda Steven , Milone Michael C.
Published: April 2023

Effect of TIL isolation treatment on CAR expression in T cells.
Supplementary Table 1-2, Supplementary Figure 1 from Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer
Authors: Wei Xiao X. , Chan Stephen , Kwek Serena , Lewis Jera , Dao Vinh , Zhang Li , Cooperberg Matthew R. , Ryan Charles J. , Lin Amy M. , Friedlander Terence W. , Rini Brian , Kane Christopher , Simko Jeffry P. , Carroll Peter R. , Small Eric J. , Fong Lawrence
Published: April 2023

Supplementary Table 1: Antibodies used in flow cytometry Supplementary Table 2: Antibodies used in immunohistochemistry Supplementary Figure 1: Pre-treatment biopsy and post-treatment RP Gleason scores
Supplemental Figure 5 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Authors: Wang Enxiu , Wang Liang-Chuan , Tsai Ching-Yi , Bhoj Vijay , Gershenson Zack , Moon Edmund , Newick Kheng , Sun Jing , Lo Albert , Baradet Timothy , Feldman Michael D. , Barrett David , Puré Ellen , Albelda Steven , Milone Michael C.
Published: April 2023

CD19-specific KIR-CAR/Dap12 shows antigen-specific cytotoxicity in vitro.
Supplemental Figure 3 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Authors: Wang Enxiu , Wang Liang-Chuan , Tsai Ching-Yi , Bhoj Vijay , Gershenson Zack , Moon Edmund , Newick Kheng , Sun Jing , Lo Albert , Baradet Timothy , Feldman Michael D. , Barrett David , Puré Ellen , Albelda Steven , Milone Michael C.
Published: April 2023

Mesothelin-specific CD3ζ CARs and SS1-KIRS2/Dap12 show comparable antigen-specific in vitro cytotoxicity toward EM-meso cells.
Supplemental Figure 2 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Authors: Wang Enxiu , Wang Liang-Chuan , Tsai Ching-Yi , Bhoj Vijay , Gershenson Zack , Moon Edmund , Newick Kheng , Sun Jing , Lo Albert , Baradet Timothy , Feldman Michael D. , Barrett David , Puré Ellen , Albelda Steven , Milone Michael C.
Published: April 2023

SS1-KIRS2 does not affect endogenous TCR expression.
Supplementary Figure Legends from Programmed Cell Death Ligand 1 Expression in Osteosarcoma
Authors: Shen Jacson K. , Cote Gregory M. , Choy Edwin , Yang Pei , Harmon David , Schwab Joseph , Nielsen G. Petur , Chebib Ivan , Ferrone Soldano , Wang Xinhui , Wang Yangyang , Mankin Henry , Hornicek Francis J. , Duan Zhenfeng
Published: April 2023

PDF file - 53K
Supplementary Methods from VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
Authors: Wu Xinqi , Giobbie-Hurder Anita , Liao Xiaoyun , Lawrence Donald , McDermott David , Zhou Jun , Rodig Scott , Hodi F. Stephen
Published: April 2023

Isolation and culture of tumor associated endothelial cells and mesenchymal stem cells. T cell adhesion assay and transendothelial migration assay. Phenotyping and enumeration of circulating endothelial cells (CEC) in whole blood sample.
Figures S1 and S2 from VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
Authors: Wu Xinqi , Giobbie-Hurder Anita , Liao Xiaoyun , Lawrence Donald , McDermott David , Zhou Jun , Rodig Scott , Hodi F. Stephen
Published: April 2023

Supplementary Figure S1. Ipi-Bev treatment altered circulating cytokine/chemokine expression. Supplementary Figure S2. Pre-treatment and post-treatment serum levels of IP-10, TNFa, IL-1a, INFa2, GRO, and IL-8 in Ipi-Bev-treated patients.
Supplementary Tables 1 - 2 from PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation
Authors: Rodić Nemanja , Anders Robert A. , Eshleman James R. , Lin Ming-Tseh , Xu Haiying , Kim Jung H. , Beierl Katie , Chen Shuming , Luber Brandon S. , Wang Hao , Topalian Suzanne L , Pardoll Drew M. , Taube Janis M.
Published: April 2023

Melanocytic archival specimens analyzed for PD-L1 expression, BRAF mutational status, and inflammatory infiltrate. PD-L1 and MHC I induction by IFN-g on cultured human melanoma cell lines, according to BRAF codon 600 genotype.
Supplemental Figure 4 from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
Authors: Fromm George , de Silva Suresh , Giffin Louise , Xu Xin , Rose Jason , Schreiber Taylor H.
Published: April 2023

Supplemental Figure 4 supports main Figure 4 and provides detailed cell phenotype and gene expression characterization of ComPACT/OX40L in the 3T3/Ova/OT-I model system.
Supplemental Figure 3 from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
Authors: Fromm George , de Silva Suresh , Giffin Louise , Xu Xin , Rose Jason , Schreiber Taylor H.
Published: April 2023

Supplemental Figure 3 supports main Figure 3 and provides OT-I expansion and FoxP3 data using the 3T3/Ova/OT-I model system.
Supplemental Figure 2 from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
Authors: Fromm George , de Silva Suresh , Giffin Louise , Xu Xin , Rose Jason , Schreiber Taylor H.
Published: April 2023

Supplemental Figure 2 provides the molecular characterization of all vaccine cell lines used in this manuscript.
Supplemental Figure 1 from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
Authors: Fromm George , de Silva Suresh , Giffin Louise , Xu Xin , Rose Jason , Schreiber Taylor H.
Published: April 2023

Supplemental Figure 1 provides mechanism of action schematics for gp96-Ig vaccination, T cell costimulation and lists the agonist antibodies used in this study.
Supplementary Table 7 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
Authors: Yao Jun , Caballero Otavia L. , Yung W.K. Alfred , Weinstein John N. , Riggins Gregory J. , Strausberg Robert L. , Zhao Qi
Published: April 2023

XLSX file - 14K, Supplemental Table 7: P values in expression association tests for frequently expressed CTs.
Supplementary Figures 1 through 3 from Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma
Authors: Freimark Bruce D. , Gong Jian , Ye Dan , Gray Michael J. , Nguyen Van , Yin Shen , Hatch Michaela M.S. , Hughes Christopher C.W. , Schroit Alan J. , Hutchins Jeff T. , Brekken Rolf A. , Huang Xianming
Published: April 2023

Supplemental figure 1. Binding of mch1N11 antibody to PS in the presence of mouse beta 2-glycoprotein I. Supplemental Figure 2. Quantitative immunohistochemistry of K1735 tumors following combination therapy of PS-targeting antibody and anti-PD-1 antibody. Supplemental figure 3. Enhanced Production of IFNgamma by Splenocytes of Combination Therapy-treated Animals is Dependent on Presence of Tumor.
Supplementary Table 4 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
Authors: Yao Jun , Caballero Otavia L. , Yung W.K. Alfred , Weinstein John N. , Riggins Gregory J. , Strausberg Robert L. , Zhao Qi
Published: April 2023

XLSX file - 34K, Supplemental Table S4. Estimated overexpression frequencies of CT genes in human cancer subtypes.
Supplementary Table 3 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
Authors: Yao Jun , Caballero Otavia L. , Yung W.K. Alfred , Weinstein John N. , Riggins Gregory J. , Strausberg Robert L. , Zhao Qi
Published: April 2023

XLSX file - 22K, Supplemental Table S3. Estimated overexpression frequencies of CT genes in human cancers.
Supplementary Table 2 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
Authors: Yao Jun , Caballero Otavia L. , Yung W.K. Alfred , Weinstein John N. , Riggins Gregory J. , Strausberg Robert L. , Zhao Qi
Published: April 2023

PDF file - 13K, Supplemental Table S2. List of TCGA tumors and sample numbers used in this study.
Supplemental Methods, Figures 1 - 4 from Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
Authors: Xu Hong , Cheng Ming , Guo Hongfen , Chen Yuedan , Huse Morgan , Cheung Nai-Kong V.
Published: April 2023

Supplemental Figure S1: Tumor free survival in humanized DKO mice. Supplemental Figure S2: T cell survival in the sc tumors. Supplemental Figure S3: Efficacy of hu3F8-BsAb vs. 5HLDS(15)BA(Y) in humanized DKO mice. Supplemental Figure S4: Cytokine release from different BsAb formats.
Supplementary Figure Legend from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
Authors: Yao Jun , Caballero Otavia L. , Yung W.K. Alfred , Weinstein John N. , Riggins Gregory J. , Strausberg Robert L. , Zhao Qi
Published: April 2023

PDF file - 61K
Supplmentary Figures 1-5 and Tables 1-2 from A Rapid Embryonic Stem Cell–Based Mouse Model for B-cell Lymphomas Driven by Epstein–Barr Virus Protein LMP1
Authors: Ba Zhaoqing , Meng Fei-Long , Gostissa Monica , Huang Pei-Yi , Ke Qiang , Wang Zhe , Dao Mai N. , Fujiwara Yuko , Rajewsky Klaus , Zhang Baochun , Alt Frederick W.
Published: April 2023

Figure S1. Flow cytometry measurement of peripheral blood B and T cells in indicated CLT RDBC chimeras and control mice. Figure S2. Comparative measurement of splenic and peripheral blood B-cell populations in the indicated CLT RDBC chimeras and control mice. Figure S3. CLT; AID-/- mice generated from germline breeding. Figure S4. Spleen size distributions of indicated CLT RDBC chimera cohorts. Figure S5. Southern blotting analyses of B-cell expansions from CLT (A) and CLT as well as CLT; AID-/- RDBC (B) chimeras. Table S1. CLT chimeras shown in Figure 2. Table S2. CLT and CLT; AID-/- chimeras shown in Figure 4.
Supplementary Figure 1B from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
Authors: Yao Jun , Caballero Otavia L. , Yung W.K. Alfred , Weinstein John N. , Riggins Gregory J. , Strausberg Robert L. , Zhao Qi
Published: April 2023

PDF file - 516K,Gene expression heatmaps for BRCA, KIRC, GBM, LUAD and UCEC. Survival curves for KIRC, LUAD and UCEC.
Supplementary Figure 1 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
Authors: Yao Jun , Caballero Otavia L. , Yung W.K. Alfred , Weinstein John N. , Riggins Gregory J. , Strausberg Robert L. , Zhao Qi
Published: April 2023

PDF file - 594K, Gene expression heatmaps for BRCA, KIRC, GBM, LUAD and UCEC. Survival curves for KIRC, LUAD and UCEC.
Supplementary figure legends from IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
Authors: Sim Geok Choo , Liu Chengwen , Wang Ena , Liu Hui , Creasy Caitlin , Dai Zhimin , Overwijk Willem W. , Roszik Jason , Marincola Francesco , Hwu Patrick , Grimm Elizabeth , Radvanyi Laszlo
Published: April 2023

Supplementary figure legend 1-11
Supplementary Figures 1 through 11 from IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
Authors: Sim Geok Choo , Liu Chengwen , Wang Ena , Liu Hui , Creasy Caitlin , Dai Zhimin , Overwijk Willem W. , Roszik Jason , Marincola Francesco , Hwu Patrick , Grimm Elizabeth , Radvanyi Laszlo
Published: April 2023

Supplementary Figure 1. Dose response in Treg and NK cell subsets upon WT IL-2 or F42K stimulation Supplementary Figure 2. Gating strategy for Tregs upon WT IL-2 or F42K stimulation Supplementary Figure 3. CD127 expression by ICOS+ Tregs and CD4+Foxp3- effector T cells Supplementary Figure 4. KI67 expression by NK cells after WT IL-2 or F42K stimulation Supplementary Figure 5. Effect of IL-2 mutant on purified cell populations Supplementary Figure 6. NK cell phenotype 3 days after WT IL-2 or F42K stimulation Supplementary Figure 7. Expression of activation markers by NK cells 6 days after WT IL-2 or F42K stimulation Supplementary Figure 8. Expression of inhibitory molecules by NK cell after WT IL-2 or F42K stimulation Supplementary Figure 9. Expression of cytolytic mediators by NK cells 6 days after WT IL-2 or F42K stimulation Supplementary Figure 10. IL-2 serum level post hydrodynamic gene transfer in mouse model Supplementary Figure 11. Changes of ICOS+ Tregs and NK cells in mouse model Supplementary Table 1. Immune response-related genes differentially regulated in F42K to WT IL-2
Supplemental Figure Legend from PD-1 Restrains Radiotherapy-Induced Abscopal Effect
Authors: Park Sean S. , Dong Haidong , Liu Xin , Harrington Susan M. , Krco Christopher J. , Grams Michael P. , Mansfield Aaron S. , Furutani Keith M. , Olivier Kenneth R. , Kwon Eugene D.
Published: April 2023

Supplemental Figure Legend
Supplemental Figures 1-3 from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines
Authors: Jaime-Ramirez Alena C. , McMichael Elizabeth L. , Kondadasula SriVidya , Skinner Cassandra C. , Mundy-Bosse Bethany L. , Luedke Eric , Jones Natalie B. , Mani Aruna , Roda Julie , Karpa Volodymyr , Li Hong , Li Jilong , Elavazhagan Saranya , La Perle Krista M. , Schmitt Alessandra C. , Lu Yanhui , Zhang Xiaoli , Pan Xueliang , Mao Hsaioyin , Davis Melanie , Jarjoura David , Butchar Jonathan P. , Poi Ming , Phelps Mitch , Tridandapani Susheela , Byrd John C. , Caligiuri Michael A. , Lee Robert J. , Carson William E.
Published: April 2023

Supplemental Figure 1.Fâ€‘IgG and IL-12 mediated NK cell lysis is dependent on the folate receptor availability and does not correlate with FcR genotype. Supplemental Figure 2. MDSC inhibit NK cell lytic activity and IFN-y production. Supplemental Figure 3. CIgG-FITC and FIgG-FITC treated mouse tissues exhibit normal histological features.
Figure S3 from Tumor-Associated Macrophages Promote Epigenetic Silencing of Gelsolin through DNA Methyltransferase 1 in Gastric Cancer Cells
Authors: Wang Hao-Chen , Chen Chin-Wang , Yang Chia-Lung , Tsai I-Min , Hou Ya-Chin , Chen Chang-Jung , Shan Yan-Shen
Published: April 2023

Supplementary Figure S3. Identification of cytokines that are upregulated in AGS and U937 coculture. A, conditioned media of AGS monoculture and coculture of AGS and U937 cells was collected and subjected to cytokine arrays. B, gastric cancer cells were treated with recombinant proteins of CCL2, CCL5, IL-8, and CXCL10 for 24 hours, and the lysates were collected for detection of DNMT1 using Western blotting.
Supplemental Figures and Tables from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Authors: Zhou Jun , Mahoney Kathleen M. , Giobbie-Hurder Anita , Zhao Fengmin , Lee Sandra , Liao Xiaoyun , Rodig Scott , Li Jingjing , Wu Xinqi , Butterfield Lisa H. , Piesche Matthias , Manos Michael P. , Eastman Lauren M. , Dranoff Glenn , Freeman Gordon J. , Hodi F. Stephen
Published: April 2023

S1. Schematic diagram of specific primers for the detection of PD-L1 variants. S2. Generation of recombinant fusion proteins of PD-L1 variants. S3. Inhibitory effects of membrane-bound PD-L1 on proliferation of antigen specific CD8+ T cells. S4. Effects of cytokines on expression of PD-L1 and cell proliferation in melanoma cell lines. S5. Associations between sPD-L1 secretion and PD-L1 expression in presence or absence of cytokine. S6. Secretion of sPD-L1 and expression of membrane-bound PD-L1 in response to sodium azide. S7. Specific and different recognitions of sPD-L1 variants by anti-PD-L1 antibody clone 29E.12B1 and 130021. S8. A. Schema on recognition regions of anti-PD-L1 antibodies. B. Detection of PD-L1-HIS (Amino acid 19-239) and PD-L1-3/Ig (Amino acid 19-178) by SDS-PAGE and immunoblotting assay with 130021 antibody. S9. Impact of serum or plasma matrices in quantitative detection of sPD-L1. S10. Kinetic changes of sPD-L1all and sPD-L1L in plasma of melanoma patients receiving ipilimumab plus bevacizumab. S11. Kinetic changes of cytokines in plasma of melanoma patients receiving ipilimumab plus bevacizumab. S12. sPD-L1 in plasma of melanoma patients receiving ipilimumab. S13. Kinetic changes of sPD-L1all and sPD-L1L in sera of melanoma patients receiving ipilimumab in ECOG 1608 trial. S14. Kinetic changes of sPD-L1all and sPD-L1L in plasma of melanoma patients receiving anti-PD-1 antibody. S15. Kinetic changes of cytokines in plasma of melanoma patients receiving anti-PD-1 antibody. S16. Associations of pretreatment levels of sPD-L1 with survival after check-point blockade. S17. Associations of long term or delayed increases in sPD-L1 with survival after check-point blockade. S18. Effects of cytokines on secretions of PD-L1 variants in DC. Supplemental Table 1. A. Amino acid regions of sPD-L1 variants. B. Amino acid regions of recombinant PD-L1 proteins. Supplemental Table 2. Associations of pretreatment levels of sPD-L1 with variables.
Supplementary FigureS 1-8 from IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I–Deficient Tumors
Authors: Seo Hyungseok , Kim Byung-Seok , Bae Eun-Ah , Min Byung Soh , Han Yoon Dae , Shin Sang Joon , Kang Chang-Yuil
Published: April 2023

S1. PD-L1 or galectin-9 knock-out MC38 MHC class I-deficient tumor cells. S2. Confirmation of CD8 T cell or NK cell depletion by depleting antibody treatment. S3. Cytokine treatment increases IFN-Î³ secretion of NK cells in MHC class I-deficient tumors. S4. Enhanced anti-tumor effects of the combination treatment of IL-21 and anti-PD-1/anti-Tim-3 therapy in TC-1 and CT26 tumor models. S5. The frequency and number of intratumoral NK cells in mice treated with combination or mono therapy. S6. IL-21 with checkpoint blockade additively foster anti-tumor effects in MC38 MHC class I & galectin-9 or PD-L1 knock out tumor models. S7. IL-21 treatment induces chemokine production by TC-1 tumor cells. S8. Analysis of IFN-Î³ production in Tim-3â"€PD-1â"€ intratumoral NK cells from normal tissues of cancer patients.
Supplementary Data from Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status
Authors: Hamada Tsuyoshi , Zhang Xuehong , Mima Kosuke , Bullman Susan , Sukawa Yasutaka , Nowak Jonathan A. , Kosumi Keisuke , Masugi Yohei , Twombly Tyler S. , Cao Yin , Song Mingyang , Liu Li , da Silva Annacarolina , Shi Yan , Gu Mancang , Li Wanwan , Koh Hideo , Nosho Katsuhiko , Inamura Kentaro , Keum NaNa , Wu Kana , Meyerhardt Jeffrey A. , Kostic Aleksandar D. , Huttenhower Curtis , Garrett Wendy S. , Meyerson Matthew , Giovannucci Edward L. , Chan Andrew T. , Fuchs Charles S. , Nishihara Reiko , Giannakis Marios , Ogino Shuji
Published: April 2023

Supplementary Tables 1-3 and Supplementary Figure 1
Figure S4 from Sustained Type I Interferon Reinforces NK Cell–Mediated Cancer Immunosurveillance during Chronic Virus Infection
Authors: Oh Ji Hoon , Kim Myeong Joon , Choi Seong Jin , Ban Young Ho , Lee Heung Kyu , Shin Eui-Cheol , Lee Kyung-Mi , Ha Sang-Jun
Published: April 2023

Figure S4. shows the subcutaneous tumor growth in mice at different time points after chronic LCMV infection.
Supplementary Tables from Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
Authors: Xu-Monette Ziju Y. , Xiao Min , Au Qingyan , Padmanabhan Raghav , Xu Bing , Hoe Nicholas , Rodríguez-Perales Sandra , Torres-Ruiz Raul , Manyam Ganiraju C. , Visco Carlo , Miao Yi , Tan Xiaohong , Zhang Hongwei , Tzankov Alexandar , Wang Jing , Dybkær Karen , Tam Wayne , You Hua , Bhagat Govind , Hsi Eric D. , Ponzoni Maurilio , Ferreri Andrés J.M. , Møller Michael B. , Piris Miguel A. , van Krieken J. Han , Winter Jane N. , Westin Jason R. , Pham Lan V. , Medeiros L. Jeffrey , Rassidakis George Z. , Li Yong , Freeman Gordon J. , Young Ken H.
Published: April 2023

Supplementary Tables S1 to S5
Supplemental Figure 2 from A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer
Authors: Wen Ti , Wang Zhenning , Li Yi , Li Zhi , Che Xiaofang , Fan Yibo , Wang Shuo , Qu Jinglei , Yang Xianghong , Hou Kezuo , Zhou Wenyang , Xu Ling , Li Ce , Wang Jin , Liu Jing , Chen Liqun , Zhang Jingdong , Qu Xiujuan , Liu Yunpeng
Published: April 2023

S2. OS of GC patients based on the expression of PD-L2 in tumor cells.
Supplemental Figure 1 from A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer
Authors: Wen Ti , Wang Zhenning , Li Yi , Li Zhi , Che Xiaofang , Fan Yibo , Wang Shuo , Qu Jinglei , Yang Xianghong , Hou Kezuo , Zhou Wenyang , Xu Ling , Li Ce , Wang Jin , Liu Jing , Chen Liqun , Zhang Jingdong , Qu Xiujuan , Liu Yunpeng
Published: April 2023

S1. Separation of patients with the same TNM substaging into different risk subgroups by the immunoscore system.
Supp. Fig. 1 from Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23
Authors: Yan Juming , Allen Stacey , Vijayan Dipti , Li Xian-Yang , Harjunpää Heidi , Takeda Kazuyoshi , Liu Jing , Cua Daniel J. , Smyth Mark J. , Teng Michele W.L.
Published: April 2023

Supp Fig. 1
Figure S4 from Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo
Authors: Eisenberg Galit , Engelstein Roni , Geiger-Maor Anat , Hajaj Emma , Merims Sharon , Frankenburg Shoshana , Uzana Ronny , Rutenberg Abraham , Machlenkin Arthur , Frei Gabi , Peretz Tamar , Lotem Michal
Published: April 2023

The addition of seSLAMF6 to IL-2 has no synergistic effect on cytotoxicity
Supplementary figures S1-S6 from All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages
Authors: Zhou Qian , Xian Miao , Xiang Senfeng , Xiang Danyan , Shao Xuejing , Wang Jincheng , Cao Ji , Yang Xiaochun , Yang Bo , Ying Meidan , He Qiaojun
Published: April 2023

S1. Macrophages activate the immunological function. S2. The effect of ATRA on proliferation and M1 polarization of macrophages. S3. RM's effect on K7M2 WT cells and ATRA abrogates migration-promoting feature of M2 macrophages in K7M2 WT cells. S4. ATRA eliminates migration-promoting feature of M2 macrophages in KHOS/NP and U2OS cells. S5. ATRA didn't inhibit the activation of STAT3/6, C/EBPβ and MAPK induced by IL-13 and IL-4. S6. The production of MMP12 and MMP9 in RAW264.7 and K7M2 WT cells.
Figure S2 from Modulation of Endoplasmic Reticulum Stress Controls CD4+ T-cell Activation and Antitumor Function
Authors: Thaxton Jessica E. , Wallace Caroline , Riesenberg Brian , Zhang Yongliang , Paulos Chrystal M. , Beeson Craig C. , Liu Bei , Li Zihai
Published: April 2023

Efficient deletion of gp96 in CD4creHsp90b1flox/flox mice and assessment of TCRvβ chains
Supplementary Data from Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy
Authors: You Wenjie , Li Lijun , Sun Deqiao , Liu Xueqing , Xia Zongjun , Xue Shan , Chen Bi , Qin Hui , Ai Jing , Jiang Handong
Published: April 2023

Supplementary Table 1, Supplementary Figures 1-7
Supplementary Table 8 from Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy
Authors: Ji Dengbo , Yi Haizhao , Zhang Dakui , Zhan Tiancheng , Li Zhaowei , Li Ming , Jia Jinying , Qiao Meng , Xia Jinhong , Zhai Zhiwei , Song Can , Gu Jin
Published: April 2023

Supplementary Table 8. CD28_co-stimulatory signal
Supplementary Table 7 from Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy
Authors: Ji Dengbo , Yi Haizhao , Zhang Dakui , Zhan Tiancheng , Li Zhaowei , Li Ming , Jia Jinying , Qiao Meng , Xia Jinhong , Zhai Zhiwei , Song Can , Gu Jin
Published: April 2023

Supplementary Table 7. All differentially expressed genes
Supplementary Table 1-5 and 10-12. Supplementary Figure 1-10. from Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy
Authors: Ji Dengbo , Yi Haizhao , Zhang Dakui , Zhan Tiancheng , Li Zhaowei , Li Ming , Jia Jinying , Qiao Meng , Xia Jinhong , Zhai Zhiwei , Song Can , Gu Jin
Published: April 2023

Supplementary Table 1-5 and 10-12. Supplementary Figure 1-10.
Supplementary Figures and Tables from PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function
Authors: Whelan Sarah , Ophir Eran , Kotturi Maya F. , Levy Ofer , Ganguly Sudipto , Leung Ling , Vaknin Ilan , Kumar Sandeep , Dassa Liat , Hansen Kyle , Bernados David , Murter Benjamin , Soni Abha , Taube Janis M. , Fader Amanda Nickles , Wang Tian-Li , Shih Ie-Ming , White Mark , Pardoll Drew M. , Liang Spencer C.
Published: April 2023

Supplementary Figures and Tables
supplementary figure 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes
Authors: Aznar M. Angela , Labiano Sara , Diaz-Lagares Angel , Molina Carmen , Garasa Saray , Azpilikueta Arantza , Etxeberria Iñaki , Sanchez-Paulete Alfonso R. , Korman Alan J. , Esteller Manel , Sandoval Juan , Melero Ignacio
Published: April 2023

No change in memory naive proportions and their DNA methylation in relevant genes
Supplementary Table 3 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes
Authors: Aznar M. Angela , Labiano Sara , Diaz-Lagares Angel , Molina Carmen , Garasa Saray , Azpilikueta Arantza , Etxeberria Iñaki , Sanchez-Paulete Alfonso R. , Korman Alan J. , Esteller Manel , Sandoval Juan , Melero Ignacio
Published: April 2023

Primer sequences
Supplementary Table 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes
Authors: Aznar M. Angela , Labiano Sara , Diaz-Lagares Angel , Molina Carmen , Garasa Saray , Azpilikueta Arantza , Etxeberria Iñaki , Sanchez-Paulete Alfonso R. , Korman Alan J. , Esteller Manel , Sandoval Juan , Melero Ignacio
Published: April 2023

DNA methylation array results with urelumab
Figures S1 to S15 from Enhanced Cancer Immunotherapy with Smad3-Silenced NK-92 Cells
Authors: Wang Qing-Ming , Tang Patrick Ming-Kuen , Lian Guang-Yu , Li Chunjie , Li Jinhong , Huang Xiao-Ru , To Ka-Fai , Lan Hui-Yao
Published: April 2023

Figures S1 to S15
Supplementary Video 1 from Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
Authors: Oei Vincent Yi Sheng , Siernicka Marta , Graczyk-Jarzynka Agnieszka , Hoel Hanna Julie , Yang Weiwen , Palacios Daniel , Almåsbak Hilde , Bajor Malgorzata , Clement Dennis , Brandt Ludwig , Önfelt Björn , Goodridge Jodie , Winiarska Magdalena , Zagozdzon Radoslaw , Olweus Johanna , Kyte Jon-Amund , Malmberg Karl-Johan
Published: April 2023

Supplementary Video 1. Time-lapse sequence of a serial killer NK cell attacking a cluster of six 221 cells in a 50Ã-50Ã-300 Î¼m3 microwell. The movie plays the same sequence simultaneously side-by-side in fluorescence (left) and bright field (right). The NK cell is shown in blue (in both panels), live targets are shown in green and dead targets in red. At the end of the movie five target cells have been killed. Total imaging time was 4.5 hours with 10 minutes between frames.
Supplementary Table 1 from Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15 Trans-Presentation
Authors: Borrelli Cristiana , Ricci Biancamaria , Vulpis Elisabetta , Fionda Cinzia , Ricciardi Maria Rosaria , Petrucci Maria Teresa , Masuelli Laura , Peri Agnese , Cippitelli Marco , Zingoni Alessandra , Santoni Angela , Soriani Alessandra
Published: April 2023

Table S1. Patient characteristics Analysis of patient characteristics used in the set of experiments in Figure 3. Ig=immunoglobulin; PC=plasma cell.
Supplementary Figure S1 from Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance
Authors: Hennequart Marc , Pilotte Luc , Cane Stefania , Hoffmann Delia , Stroobant Vincent , Plaen Etienne De , Eynde Benoît J. Van den
Published: April 2023

Inhibition of the IFNg or PKA pathway does not reduce constitutive IDO1 expression.
Supplementary Figure S1 from Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs
Authors: Miyao Kotaro , Terakura Seitaro , Okuno Shingo , Julamanee Jakrawadee , Watanabe Keisuke , Hamana Hiroshi , Kishi Hiroyuki , Sakemura Reona , Koyama Daisuke , Goto Tatsunori , Nishida Tetsuya , Murata Makoto , Kiyoi Hitoshi
Published: April 2023

Sequence data of CD3 and ATAM
Supplemental Figures and Tables from Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37
Authors: Sarhan Dhifaf , Hippen Keli L. , Lemire Amanda , Hying Skyler , Luo Xianghua , Lenvik Todd , Curtsinger Julie , Davis Zachary , Zhang Bin , Cooley Sarah , Cichocki Frank , Blazar Bruce R. , Miller Jeffrey S.
Published: April 2023

Supplemental Figures and Tables
Supplementary Figure 1 from Automated Analysis of Lymphocytic Infiltration, Tumor Budding, and Their Spatial Relationship Improves Prognostic Accuracy in Colorectal Cancer
Authors: Nearchou Ines P. , Lillard Kate , Gavriel Christos G. , Ueno Hideki , Harrison David J. , Caie Peter D.
Published: April 2023

Supplementary Figure 1. Study Design Workflow
Table S4 from Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort
Authors: Iorgulescu J. Bryan , Harary Maya , Zogg Cheryl K. , Ligon Keith L. , Reardon David A. , Hodi F. Stephen , Aizer Ayal A. , Smith Timothy R.
Published: April 2023

table s4